Section Arrow
HALO.NASDAQ
- Halozyme Therapeutics
Quotes are at least 15-min delayed:2025/07/20 13:09 EDT
Regular Hours
Last
 56.45
-1.355 (-2.34%)
Day High 
57.85 
Prev. Close
57.805 
1-M High
58.56 
Volume 
1.11M 
Bid
56
Ask
58.35
Day Low
56.38 
Open
57.85 
1-M Low
51.06 
Market Cap 
7.12B 
Currency USD 
P/E 15.37 
%Yield -- 
10-SMA 56.54 
20-SMA 54.7 
50-SMA 55.19 
52-W High 70.505 
52-W Low 42.01 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
3.76/7.06
Enterprise Value
8.63B
Balance Sheet
Book Value Per Share
3.91
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
1.02B
Operating Revenue Per Share
6.34
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 13:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.